American Journal of Obstetrics & Gynecology
Volume 195, Issue 4 , Pages 1114-1118, October 2006

Prevalence of factor V Leiden, prothrombin and methylene tetrahydrofolate reductase mutations in women with adverse pregnancy outcomes in Lebanon

  • Laila F. Zahed, PhD

      Affiliations

    • Departments of Pathology and Laboratory Medicine
  • ,
  • Roni F. Rayes, MSc

      Affiliations

    • Departments of Pathology and Laboratory Medicine
  • ,
  • Rami A. Mahfouz, MD

      Affiliations

    • Departments of Pathology and Laboratory Medicine
  • ,
  • Ali T. Taher, MD

      Affiliations

    • Internal Medicine
  • ,
  • Huda H. Maarouf, MD

      Affiliations

    • Obstetrics and Gynecology, American University of Beirut Medical Center, Beirut, Lebanon
  • ,
  • Anwar H. Nassar, MD

      Affiliations

    • Obstetrics and Gynecology, American University of Beirut Medical Center, Beirut, Lebanon

Received 8 March 2006; received in revised form 10 June 2006; accepted 29 June 2006.

Objective

The purpose of this study was to determine the prevalence of factor V Leiden, prothrombin, and methylene tetrahydrofolate reductase gene mutations in women with adverse pregnancy outcome compared with women who had uneventful pregnancies.

Study design

Between 2003 and 2005, pregnant women with ≥1 unexplained second trimester abortion, ≥1 intrauterine fetal death, severe preeclampsia, or severe intrauterine growth restriction (study subjects) were compared with control subjects (uneventful pregnancy) for the frequency of the mutations.

Results

The cases of 91 patients in each arm were analyzed. Obstetric complications were second trimester abortions (16.5%), intrauterine fetal death (53.8%), preeclampsia (8.8%), and severe intrauterine growth restriction (20.9%). Study subjects were more likely to be older and multiparous compared with control subjects. The 2 groups showed no difference in the incidence of smoking or family history of thrombosis, but study subjects were more likely to have a positive family history of obstetric complications. The prevalence of factor V Leiden (12.1% vs 18.7%; P = .304), prothrombin (7.7% vs 5.5%; P = .765), methylene tetrahydrofolate reductase gene mutations (53.8% vs 65.9%; P = .130), and >1 mutation (11.0% vs 17.6%; P = .290) was not significantly different between study subjects and control subjects.

Conclusion

Factor V Leiden, prothrombin, and methylene tetrahydrofolate reductase gene mutations did not seem to play a significant role in adverse pregnancy outcome in our population.

Key words: Thrombophilia, Pregnancy outcome, Obstetric complication

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by grants from American University of Beirut–University Research Board grant no. DCU114160.034130.Presented at the 26th Annual Meeting of the Society for Maternal Fetal Medicine, January 30-February 4, 2006, Miami, FL.Reprints not available from the authors.

PII: S0002-9378(06)00865-9

doi:10.1016/j.ajog.2006.06.082

American Journal of Obstetrics & Gynecology
Volume 195, Issue 4 , Pages 1114-1118, October 2006